ReviewJournal of cancer research and clinical oncology2006
Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches.
Review in Journal of cancer research and clinical oncology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Optimal sequential therapy using tyrosine kinase inhibitors as the first-line treatment in patients with metastatic renal cell carcinoma: A nationwide multicenter study.Asian journal of urology · 2024Article
- Association between PD-L1 Expression and the Prognosis and Clinicopathologic Features of Non-Clear Cell Renal Cell Carcinoma.International journal of molecular sciences · 2024Article
- A novel biflavone fromFrontiers in pharmacology · 2022Article
- Notch signaling plays a crucial role in cancer stem-like cells maintaining stemness and mediating chemotaxis in renal cell carcinoma.Journal of experimental & clinical cancer research : CR · 2017Article
- Autocrine and paracrine STIP1 signaling promote osteolytic bone metastasis in renal cell carcinoma.Oncotarget · 2017Article
- Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?Medical oncology (Northwood, London, England) · 2016Article
- Telmisartan induces apoptosis and regulates Bcl-2 in human renal cancer cells.Experimental biology and medicine (Maywood, N.J.) · 2015Article
- Clinical behavior of chromophobe renal cell carcinoma is less aggressive than that of clear cell renal cell carcinoma, independent of Fuhrman grade or tumor size.Virchows Archiv : an international journal of pathology · 2014Article
- MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines.Therapeutic advances in vaccines · 2014Review
- Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma.British journal of cancer · 2013Article
- Effects of oleic acid on cell proliferation through an integrin-linked kinase signaling pathway in 786-O renal cell carcinoma cells.Oncology letters · 2013Article
- Notch1 activation promotes renal cell carcinoma growth via PI3K/Akt signaling.Cancer science · 2012Article
- [Incidence and long-term prognosis of papillary renal cancer. Results of a retrospective multicenter study].Der Urologe. Ausg. A · 2011Article
- Inactivation of Lactobacillus leichmannii ribonucleotide reductase by 2',2'-difluoro-2'-deoxycytidine 5'-triphosphate: covalent modification.Biochemistry · 2010Article
- Overweight is associated with improved cancer-specific survival in patients with organ-confined renal cell carcinoma.Journal of cancer research and clinical oncology · 2009Article
- Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses.Cancer immunology, immunotherapy : CII · 2009Article
- TGF-alpha as a candidate tumor antigen for renal cell carcinomas.Cancer immunology, immunotherapy : CII · 2009Article
- Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?BMC cancer · 2009Article
- Incidence and long-term prognosis of papillary renal cell carcinoma.Journal of cancer research and clinical oncology · 2009Article
- Immunotherapy of renal cell carcinoma.Cancer immunology, immunotherapy : CII · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesRenal cell carcinoma is an aggressive malignancy with a high propensity for both early and metachronous regional and distant metastasis. While surgical resection is the mainstay of therapy for patients with localized disease, the prognosis for patients with distant metastasis is poor with a 5-year survival rate of less than 10%. Response rates to first-line immunotherapy or immunochemotherapy range from 10-35%; responses achieved are predominantly partial remissions of short duration. Until today, there is no standard therapeutic procedure for the growing number of patients who relapse following first-line therapy and desire further active treatment. MATERIALS AND
methodsThis article reviews classic and recent publications about second- and third-line approaches, their potential efficacy and toxicity.
resultsSeveral novel approaches have raised well-founded hope. Especially the application of monoclonal antibodies targeting VEGF signalling as well as different receptor tyrosine kinase inhibitors have the potential to change the face of second-line treatment of patients with metastatic RCC. Both groups of agents are focused in current phase III trials, either as mono- and/or combination therapy.
conclusionsUntil today, second-line treatment of patients with metastatic RCC progressing under therapy with biological response modifiers remains an unresolved issue. The results of ongoing clinical trials evaluating novel targeted approaches can be expected with suspense.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.